Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
NCT02883153
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Renal Cell Carcinoma
Interventions
DRUG:
Zirconium-89 girentuximab PET/CT
Sponsor
Radboud University Medical Center